T. Rowe Price Associates’s VYNE Therapeutics VYNE Stock Holding History

T. Rowe Price Associates’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21	Closed	-$20K	–	3021
2021 Q4	$20K	Hold	21	–	–	﹤0.01%	2960
2021 Q3	$27K	Sell	21 -24	-53%	-$46.5K	﹤0.01%	2927
2021 Q2	$141K	Buy	45 +9	+25%	+$35.6K	﹤0.01%	2790
2021 Q1	$222K	Buy	+36	New	+$261K	﹤0.01%	2659
2020 Q4	–	Sell	-3	Closed	-$17K	–	2721
2020 Q3	$17K	Buy	+3	New	+$17.5K	﹤0.01%	2586
2020 Q1	–	Sell	-144	Closed	-$2.4M	–	2565
2019 Q4	$2.4M	Sell	144 -7	-5%	-$117K	﹤0.01%	1553
2019 Q3	$2.43M	Sell	151 -15	-9%	-$242K	﹤0.01%	1530
2019 Q2	$3.58M	Sell	166 -1	-0.6%	-$24.7K	﹤0.01%	1442
2019 Q1	$4.71M	Buy	167 +1	+0.6%	+$24K	﹤0.01%	1411
2018 Q4	$2.47M	Hold	166	–	–	﹤0.01%	1512
2018 Q3	$5.9M	Buy	+166	New	+$5.12M	﹤0.01%	1439

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

T. Rowe Price Associates's VYNE Position: Q1 2022 in Review

T. Rowe Price Associates sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 21 shares — an estimated $20K sold.

T. Rowe Price Associates first reported a position in VYNE in Q3 2018 and held it in 11 quarters. The position peaked at $5.9M in Q3 2018. 41 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

T. Rowe Price Associates reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
T. Rowe Price Associates sold 21 VYNE Therapeutics shares in Q1 2022, an estimated $20K.
T. Rowe Price Associates first reported a position in VYNE Therapeutics in Q3 2018 and held it in 11 quarters.
T. Rowe Price Associates's VYNE Therapeutics position peaked at $5.9M in Q3 2018.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.